StocksDeepDive
Snapshot · Russell 3000 · generated 2026-09-19 21:53 UTC

GYRE — Gyre Therapeutics, Inc.

EXPENSIVE (MOS -6191.7%) · Quality 49/100

Price
7.55
Intrinsic value
0.12
Margin of safety
-6191.7%
Implied growth (reverse DCF)
+60.0%
model assumes +0.0%
Value Score
-5.3
Quality
49
Psychology
-44.4
Discovery
133
price/volume attention only
Moat score
46.8
erosion: none

Value Score: bottom 2% of Russell 3000 · Quality: bottom 36%

Open the interactive Deep Dive for GYRE →

Use this data programmatically

This page's numbers are also available as JSON at /api/v1/deep-dive/GYRE - see the API docs for the full read-only surface, including an MCP server for AI assistants.

Common questions

Is GYRE undervalued?

As of 2026-09-19, GYRE trades at 7.55 against a computed intrinsic value of 0.12 (-6191.7% margin of safety) - StocksDeepDive's valuation label for this is EXPENSIVE. This is a described calculation from public data, not a recommendation.

What is Gyre Therapeutics, Inc.'s Value Score?

Gyre Therapeutics, Inc.'s Value Score is -5.3 as of 2026-09-19 - it combines value, quality, crowd psychology and market attention into one number.